Innovative Product Leadership Neomend's flagship product, Progel PALS, is the only FDA-approved pleural air leak sealant in the U.S., demonstrating a strong foothold in specialized surgical wound management and a potential for expansion into other thoracic and surgical applications.

Strong Clinical Evidence The company's clinical study results showing significant reductions in intraoperative air leaks and hospital stays highlight its product's effectiveness, making it an attractive solution for hospitals seeking to improve patient outcomes and reduce costs.

Growing Market Opportunity With approximately 150,000 lung resections performed annually in the U.S., there is a substantial market for airway sealing products, and Neomend is positioned to capitalize on increasing demand within thoracic surgery centers.

Advanced Technology Platform Neomend’s proprietary hydrogel technology supports the development of diverse wound care applications, offering potential for broadening its product portfolio and entering new segments such as post-surgical adhesion prevention and drug delivery systems.

Funding for Expansion With $20 million in funding and a revenue range of $1M to $10M, Neomend has the financial backing to scale its sales efforts, develop new products, and expand its market reach within the competitive medical device landscape.